# 4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

> **NCT01039701** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 99 (actual)

## Conditions studied

- Mild to Moderate Alzheimer's Disease

## Interventions

- **DRUG:** AZD1446
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01039701
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2010-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039701, "4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01039701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*